Author

L. Wettstein

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:host-pathogen & immune response· 3 Organism:human· 2 Research Focus:drug response / drug discovery· 1 Organism:mouse· 1 Assay:protein sequence· 1 Organism:rat· 1

Frequent Co-Authors

R. Gross· 3 shared A. Kleger· 2 shared C. Conzelmann· 2 shared F. Kirchhoff· 2 shared F. Zech· 2 shared J. A. Mueller· 2 shared J. Muench· 2 shared S. Stenger· 2 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

R. Gross

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

COVID-eVax, an electroporated plasmid DNA vaccine candidate encoding the SARS-CoV-2 Receptor Binding Domain, elicits protective immune responses in animal models of COVID-19

A. Conforti, E. Marra, F. Palombo, G. Roscilli, M. Rava, V. Fumagalli, A. Muzi, M. Maffei, L. Luberto, L. Lione, E. Salvatori, M. Compagnone, E. Pinto, E. Pavoni, F. Bucci, , De F

This paper evaluates a DNA vaccine candidate, COVID-eVax, which induces strong neutralizing antibodies and T cell responses against SARS-CoV-2 in animal models, showing protective effects against viral challenge.

bioRxiv · Jun 14, 2021 · PreprintImmunology

IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition

C. Prelli Bozzo, R. Nchioua, M. Volcic, J. Krueger, S. Heller, C. M. Stuerzel, D. Kmiec, C. Conzelmann, J. A. Mueller, F. Zech, D. Schuetz, L. Koepke, E. Braun, R. Gross, L. Wettstein, , F. Kirchhoff

This study shows that IFITM proteins are required for SARS-CoV-2 infection and can be targeted to inhibit viral entry and replication.

bioRxiv · Aug 18, 2020 · PreprintMicrobiology

Alpha-1 antitrypsin inhibits SARS-CoV-2 infection

L. Wettstein, C. Conzelmann, J. A. Mueller, T. Weil, R. Gross, M. Hirschenberger, A. Seidel, S. Klute, c. Prelli-Bozzo, F. Zech, N. Preising, G. Fois, R. Lochbaum, P. Knaff, V. Mailaender, , J. Muench

The paper identifies 1-antitrypsin as a specific inhibitor of SARS-CoV-2, showing it blocks viral infection of human airway epithelium at physiological concentrations.

bioRxiv · Jul 2, 2020 · PreprintMicrobiology